UCT

What UCT does

UCT (Universal Cancer Technologies) is a Toronto-based, privately held biotechnology company developing the CA-62 Biomarker Cancer Test, a blood-based immunochemical assay that detects and quantifies the N-glycoprotein CA-62 marker for early-stage epithelial carcinoma. The biomarker is reported to peak at early, poorly differentiated tumor stages, enabling the test to claim greater than 90% sensitivity and 95% specificity (less than 5% false positives) across stage I-IV cancers including breast, prostate, colorectal, lung, ovarian, renal, melanoma, and others; performance has been demonstrated across 15 studies and 10,000+ blood samples at international centers in Canada, the United States, Russia, and Kazakhstan. The company is led by CEO and co-founder Viatcheslav Kondratiev, with subsidiaries including UCT Research & Development Inc. (Toronto) and JVS Diagnostics LLC (Russia, a Skolkovo Foundation resident), and operates with 11-50 employees.

The commercial model is a one-time, per-test kit sale (planned pricing of approximately $300 in Western markets and 6,000 rubles in Russia) sold by prescription through hospitals, oncologists, and medical facilities. Go-to-market is enterprise field sales supported by KOL engagement at major oncology conferences (ASCO 2023/2024, ISOBM 2022, Next Generation DX Summit 2024) and a physician training program. The company has secured medical device approvals in the Russian Federation and the Republic of Kazakhstan, filed for EMA centralized authorization in September 2021, and launched a US clinical trial in July 2022; granted patents include the Russian Patent (Oct 2020) and Eurasian Patent (Apr 2020), with US, EU, and India applications pending. The only disclosed funding is $400,000 from the main shareholder UCT Research & Development to subsidiary JVS Diagnostics in October 2018, and no revenue has been publicly disclosed.

Name

UCT

Legal name

Universal Cancer Technologies

Website

https://ucttest.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

UCT (Universal Cancer Technologies) is a Toronto-based private biotechnology company that has developed the CA-62 Biomarker Cancer Test, a blood-based assay for early detection of epithelial carcinomas, sold by prescription to hospitals and oncologists and currently commercialized in Russia and Kazakhstan.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Cancer diagnostics
• Biomarker testing
• Early cancer detection
• Blood-based diagnostics
• Oncology screening

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. CA-62 Biomarker Cancer Test Kit Sales: UCT generates revenue from the sale of its CA-62 Biomarker Cancer Test kits to medical facilities and hospitals. The test is available by prescription at medical facilities. Planned pricing is approximately $300 in Western markets and 6,000 rubles in Russia.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

UCT develops and commercializes the CA-62 Biomarker Cancer Test, a blood-based immunochemical assay that detects and quantifies the proprietary N-glycoprotein CA-62 biomarker from a routine blood draw. The test is designed for early-stage epithelial carcinoma detection (stages I-IV including carcinoma in-situ), with greater than 90% sensitivity and 95% specificity. It is sold to hospitals and medical facilities by prescription for screening, therapy monitoring, recurrence detection, and chemotherapy resistance identification.

Product overview

UCT offers a single unified product: the CA-62 Biomarker Cancer Test. This blood-based diagnostic test detects the N-glycoprotein CA-62 biomarker, which appears uniquely on the surface of epithelial cancer cells. The test is designed for early cancer detection, therapy monitoring, and recurrence identification across multiple epithelial cancer types including breast, prostate, lung, colorectal, ovarian, and others. UCT has developed this technology over more than a decade, with clinical validation across over 10,000 human samples and regulatory approvals in the Russian Federation and Kazakhstan.

Differentiator

Problem solved

Functional benefit

Brands

• Oncotest CA-62: Cancer test kit brand for detecting epithelial carcinomas at earliest stages

Products and services

• CA-62 Biomarker Cancer Test A blood-based diagnostic test (sold as a kit/reagent set) that detects and quantifies the N-glycoprotein CA-62 biomarker for early-stage epithelial cancer detection, offering greater than 90% sensitivity and 95% specificity. Used by oncologists, hospitals, and medical facilities for screening, therapy monitoring, recurrence detection, and chemotherapy resistance identification across multiple epithelial cancer types including breast, prostate, colorectal, lung, liver, cervical, ovarian, melanoma, intestinal, myeloma, esophageal, and glioblastoma.

Quantifiable outcome

• Greater than 90% sensitivity and 95% specificity in detecting cancer at early stages including carcinoma in-situ
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• UCM Technologies Inc.coreStrategic or Co-development Partner · 31 July 2024UCM Technologies Inc., Toronto, ON, Canada is a key research and development partner in the development of the CA-62 Biomarker Cancer Test technology. Joint research efforts have produced multiple peer-reviewed publications on the CA-62 biomarker for early cancer detection.
• Pacific Biosciences Research CentercoreStrategic or Co-development Partner · 31 July 2024Pacific Biosciences Research Center, Vancouver, BC, Canada collaborates with UCT on cancer biomarker research and development, contributing to studies on early-stage cancer detection.
• UCT Research & Development Inc.coreStrategic or Co-development Partner · 31 July 2024UCT Research & Development Inc., Toronto, ON, Canada serves as the main shareholder and R&D arm of UCT, providing funding and research support for the CA-62 biomarker technology development and commercialization.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• GRAIL: GRAIL's Galleri test is a blood-based multi-cancer early detection assay (methylation-based) targeting similar screening use cases across multiple cancer types. It is the most directly comparable peer in multi-cancer liquid biopsy screening and competes for the same physician and payer relationships UCT is targeting.
• Guardant Health: Guardant Health offers blood-based liquid biopsy tests (Guardant360, Shield) for cancer detection and monitoring. It overlaps with UCT on blood-based oncology diagnostics and recurrence/MRD monitoring use cases.
• Exact Sciences: Exact Sciences commercializes Cologuard (blood-based colorectal screening) and acquired Thrive Earlier Detection, making it a direct competitor in blood-based multi-cancer and single-cancer screening with established US commercial infrastructure and FDA-cleared products.
• Freenome: Freenome is developing a blood-based multi-cancer screening test using methylation and protein biomarkers, positioning it as a direct emerging competitor in the early-detection liquid biopsy category UCT occupies.
• Natera: Natera commercializes Signatera, a blood-based MRD and recurrence monitoring test. The recurrence monitoring and therapy monitoring applications UCT targets map directly to Natera's MRD franchise.

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling for solid tumors. It serves the same oncologist customers with tissue- and blood-based molecular diagnostics but operates as a broader, established incumbent in oncology diagnostics.
• NeoGenomics: NeoGenomics operates a large oncology-focused clinical laboratory offering solid tumor and liquid biopsy profiling. It is comparable as a broad oncology diagnostics service provider serving hospitals and oncologists with specialized cancer testing.
• Myriad Genetics: Myriad markets multiple oncology diagnostic tests (e.g., myChoice HRD, BRACAnalysis) across hereditary cancer and treatment selection. It overlaps with UCT's positioning as a molecular oncology diagnostics provider to oncologists and hospitals.

Others

• Bio-Techne: Bio-Techne supplies immunoassay reagents, antibodies, and biomarker analytical tools used in cancer biomarker development and validation. It is comparable as an enabling life-science tools supplier in the biomarker assay ecosystem UCT depends on.
• Charles River Laboratories: Charles River provides preclinical and clinical laboratory services, including biomarker and bioanalytical testing for oncology drug development. It is comparable as a CRO/lab services peer supporting cancer biomarker assay development and clinical validation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UCT